Metastatic Prostate Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Metastatic Prostate Cancer Treatment Market is segmented By Treatment Type (Hormone therapy, Chemotherapy, Biological Therapy, Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Metastatic Prostate Cancer Treatment Market Overview

The "Global Metastatic Prostate Cancer Treatment Market"  is predicted to reach at a high CAGR of 3.2% during the forecast period (2024-2031)

Metastatic cancer is a type of cancer that spreads from where it started to different parts of the body, and it is also called stage IV (4) cancer. The process by which cancer cells spread to other parts of the body is called metastasis. Prostate cancer that spread to local or distant areas of the body is called Metastatic Prostate Cancer. Prostate cancer with local metastasis means that it has spread to other body organs within the pelvis region, which usually means the nearby lymph nodes area. Distant metastasis means the prostate cancer has spread beyond the pelvic region. That is, bones, brain, liver, and lungs are common cancer metastasis sites. In many cases, it grows very slowly. Some men even do not know that they have the disease. Some symptoms are frequent urination, difficulty in controlling urination, weak or interrupted urine flow, pain or burning when urinating, erectile dysfunction, blood in the urine or semen. It can cause a range of complications; when prostate cancer metastasizes to the following areas, In Bone, this can cause fractures and pain, In the Brain, this can lead to dizziness, headaches, and seizures. In the liver, this can lead to jaundice and swelling in the abdomen, and in the lungs, this can lead to shortness of breathing. Treatments of prostate cancer include Radiation therapy, Surgery, Chemotherapy, Biological therapy, and Hormone therapy. The market is expected to drive in the future due to the high prevalence rate of Prostate cancers.

Source: DataM Intelligence Analysis (2020)

Metastatic Prostate Cancer Treatment Market Dynamics

The global Metastatic Prostate Cancer Treatment market growth is driven by the growing prevalence of Prostate cancers, and Emerging strong pipeline drugs, growing policies on reimbursement, Availability of new prostate cancer treatments are among the key factors driving the market growth.

Increasing Prevalence of Metastatic Prostate Cancers, is expected to drive the global Metastatic Prostate Cancer Treatment market during the forecast period.

According to the National Cancer Institute NIH, Prostate cancer is the fifth leading cause of cancer death in the United States. The rate of new prostate cancer cases was 109.8 per 100,000 men per year. In 2017, an estimated 3,170,339 men were living with prostate cancer in the United States. In 2020, it was estimated that there would be 191,930 new cases of prostate cancer.  According to WHO, Prostate cancer cases estimated in 2020 were 1.41 million. These factors are driving the growth of the market in the forecast period.

Emerging strong pipeline of new drugs are increasing the demand for the global Metastatic Prostate Cancer Treatment market during the forecast period.

According to new findings from 2 large clinical trials presented at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO), the treatment landscape for metastatic prostate cancer is shifting and increasing yet again. For instance, On September 17, 2019, the Food and Drug Administration approved apalutamide (Erleada) for men with metastatic, castration-sensitive prostate cancer. According to clinical trials.gov,

High treatment costs are likely to hinder the global Metastatic Prostate Cancer Treatment market growth.

According to the American Cancer Society, on average, prostate cancer costs about $4,300 initially and about $9,100 over five years, and it costs about $15,000 initially and $19,000 over five years for surgery. Hormone therapy with radiation costs about $17,500 initially and $25,000 total over five years. For patients with advanced and metastatic prostate cancer, costs can reach $100,000 or more.

COVID-19 Impact on Metastatic Prostate Cancer Treatment Market

Due to the covid-19 pandemic outbreak, the market for Global Metastatic Prostate Cancer Treatment Market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak. However, clinical trials were disrupted during this period and have not fully recovered in the post-lockdown period. Could affect the future demand for global metastatic prostate cancer treatment in the negative scenario.

Metastatic Prostate Cancer Treatment Market Segment Analysis

Based on Treatment method, the global Metastatic Prostate Cancer Treatment market is segmented into Hormone therapy, Chemotherapy, Biological therapy.

Currently, Hormone therapy dominates the global Metastatic prostate cancer treatment market and is anticipated to continue this trend throughout the forecasting period. The key factors driving the market growth include an increase in demand for hormone therapy drugs; Hormone therapy is also called androgen suppression therapy. The goal is to reduce male hormones, called androgens, in the body or stop them from fueling prostate cancer cells. Types of hormone therapy can be used to treat prostate cancer.

Androgen deprivation therapy, also called ADT, uses surgery or medicines to lower the levels of androgens made in the testicles Orchiectomy, LHRH agonists- Leuprolide (Lupron, Eligard), Goserelin (Zoladex), Triptorelin (Trelstar), Histrelin (Vantas) and Enzalutamide (Xtandi), apalutamide (Erleada) and darolutamide (Nubeqa) are newer types of anti-androgens are used in metastatic prostate cancer. Radiofrequency ablation (RFA) to help control pain in men whose prostate cancer has spread to one or more areas in the bones.

Based on the Distribution channel, the global Metastatic Prostate Cancer Treatment market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The segment is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies based on the distribution channel. Currently, the hospital pharmacies segment accounted for most prostate cancer treatment market share, owing to hospital pharmacies' strong presence across the globe, increased number of hospitalized prostate cancer patients, and convenience offered by hospital pharmacies. Online pharmacies are the fastest-growing segment during the forecast period, owing to a rise in awareness regarding online pharmacies, an increase in the number of internet users, and a surge in online purchasing of drugs over the traditional methods.

Source: DataM Intelligence Analysis (2020)

Metastatic Prostate Cancer Treatment Market Geographical Share

North America served the largest share of the market due to the increasing prevalence of Metastatic prostate cancer cases. According to the American Cancer Society, the prostate cancer prevalence in 2019 estimated was 174,650 prostate cancers and in the United States for 2021 new cases are about 248,530. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and radiation therapy methods, the total availability of advanced diagnostic tools, and many companies are developing oncology products.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to the increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, as per the university of south Australia, in 2019, more than 19,500 prostate cancer cases were diagnosed in Australia. Globally, prostate cancer cases reached 1.28 million in 2018. These factors are driving the growth of the market in the forecast period.

Source: DataM Intelligence Analysis (2020)

Metastatic Prostate Cancer Treatment Market Competitive Landscape

The global Metastatic prostate cancer treatment market is quite competitive with some key competitors like Novartis, SeleXel, Telix Pharmaceuticals, Zenith Epigenetics Ltd, Amgen, Genentech, Roche, Bayer A G, Astellas Pharma, Sanofi. The key players are adopting various growth strategies such as product launches, acquisitions, and investments in multiple sectors. For instance, According to clinicaltrials.gov;

Genentech:

Company overview- Genentech is an American biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with severe and life-threatening diseases. Their transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. It becomes a member of the Roche Group. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development operate as an independent center within Roche.

Product Portfolio: The Company’s portfolio comprised of includes Neuroscience, oncology, inflammation and immunology and Ophthalmology and others.

Key developments:

Genentech discovered Ipatasertib in partnership with Array BioPharma. Pfizer acquired the array on July 30, 2019.

Why Purchase the Report?

• Visualize the composition of the global Metastatic Prostate Cancer Treatment market segmentation by Product Type, by Application, by End-User, and region highlighting the key commercial assets and players.
• Identify commercial opportunities in the Metastatic Prostate Cancer Treatment market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of Metastatic Prostate Cancer Treatment market-level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The global Metastatic Prostate Cancer Treatment report would provide an access to an approx. market data tables figure 180 pages.

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers